IP Library Granted Patent US 9,527,838
Granted Patent B2
US 9,527,838 · App. 14/652,944 · Granted Dec 27, 2016

2-pyridinecarboxamide derivatives, compositions containing such compounds, and methods of treatment

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,527,838
App. No.
14/652,944
Granted
Dec 27, 2016
Kind
B2
Abstract

Novel pyridine-2-carboxamide derivatives of formula I and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are effective as glucokinase activating agents. Pharmaceutical compositions and methods of treatment are also included. The present invention relates to novel pyridine-2-carboxamide derivatives and salts thereof which are effective as glucokinase activating agents. Moreover, it relates to compositions containing such compounds, and methods of treatment.

Claims (76)

1. A compound of formula I:

or a pharmaceutically acceptable salt thereof, wherein:

R 1 is triazol, pyridyl or phenyl, optionally substituted with 1-4 substituents independently selected from: halogen, hydroxy, oxo, C 1-6 alkyl, C 1-6 alkylOC 1-6 alkyl, C 1-6 alkoxy, CN, NR 3 R 4 , C(O) 1-2 C 1-6 alkyl, C 1-6 alkylC(O) 1-2 C 1-6 alkyl or arylC 1-6 alkyl, wherein the alkyl and alkoxy substituents are further optionally substituted by 1-4 substituents independently selected from: halogen or C 1-6 alkyl where said C 1-6 alkyl is optionally substituted by 1-6 halogens;

R 2 is phenyl, optionally substituted with 1-4 substituents independently selected from: halogen, hydroxy, oxo, C 1-6 alkyl, C 1-6 alkylOC 1-6 alkyl, C 1-6 alkoxy, CN, NR 3 R 4 , C(O) 1-2 C 1-6 alkyl, C 1-6 alkylC(O) 1-2 C 1-6 alkyl or arylC 1-6 alkyl, wherein the alkyl and alkoxy substituents are further optionally substituted by 1-4 substituents independently selected from: halogen or C 1-6 alkyl where said C 1-6 alkyl is optionally substituted by 1-6 halogens;

ring A is thiazolyl which, in addition to the -L-T substituent, is further optionally substituted with 1-4 substituents independently selected from: halogen, hydroxy, C 1-6 alkyl, C 1-6 alkylOC 1-6 alkyl, C 1-6 alkoxy, CN, NR 3 R 4 , C(O) 1-2 C 1-6 alkyl or C 1-6 alkylC(O) 1-2 C 1-6 alkyl, wherein the alkyl and alkoxy substituents are further optionally substituted by 1-4 substituents independently selected from: halogen, C 1-6 alkyl or C 1-6 alkoxy where the alkyl and alkoxy substituents are optionally substituted by 1-6 halogens,

L represents C 1-6 alkyl, C 1-6 alkylOC 1-6 alkyl, C 1-6 alkoxy, NR 3 R 4 , C 1-6 alkylNR 3 R 4 or S(O) 0-2 C 1-6 alkyl, wherein the alkyl and alkoxy groups are further optionally substituted by 1-4 substituents independently selected from: halogen or C 1-6 alkyl where said C 1-6 alkyl is optionally substituted by 1-6 halogens,

T represents CO 2 R, CONR 3 R 4 , or P(O)(OR 5 ) 2 ,

R is hydrogen, and

R 3 , R 4 , and R 5 are individually selected from hydrogen or C 1-6 alkyl.

2. The compound of claim 1 , wherein R 1 is triazolyl, substituted with C 1-6 alkyl optionally substituted by 1-3 halogen; or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , wherein R 1 is pyridyl; or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 , wherein R 1 is phenyl, optionally substituted with 1-4 substituents independently selected from: halogen or C 1-6 alkyl, wherein the alkyl is further optionally substituted by 1-6 halogen substituents; or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 , wherein R 2 is phenyl, optionally substituted with 1-4 substituents independently selected from: halogen, C 1-6 alkoxy, or C 1-6 alkyl, wherein the alkyl and alkoxy substituents are further optionally substituted by 1-6 halogen substituents; or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 , wherein L represents C 1-6 alkyl or S(O) 0-2 C 1-6 alkyl, further optionally substituted by 1-6 halogen substituents; or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1 , wherein L represents —SCH 2 —, SC(CH 3 ) 2 —, —SCH 2 C(CH 3 ) 2 —, —CH 2 CH 2 — or —CH 2 —; or a pharmaceutically acceptable salt thereof.

8. A compound which is:

Ethyl ({2-[({3-[(4-methoxyphenyl)sulfanyl]-6-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]pyridin-2-yl}carbonyl)amino]-1,3-thiazol-5-yl}sulfanyl)acetate;

({2-[({3-[(4-methoxyphenyl)sulfanyl]-6-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]pyridin-2-yl}carbonyl)amino]-1,3-thiazol-5-yl}sulfanyl)acetic acid;

3-[(4-methoxyphenyl)sulfanyl]-N-(5-{[2-(methyl amino)-2-oxoethyl]sulfanyl}-1,3-thiazol-2-yl)-6-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]pyridine-2-carboxamide;

2-({2-[({3-[(4-methoxyphenyl)sulfanyl]-6-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]pyridin-2-yl}carbonyl)amino]-1,3-thiazol-5-yl}sulfanyl)-2-methylpropanoic acid;

Ethyl 3-({2-[({3-[(4-methoxyphenyl)sulfanyl]-6-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]pyridin-2-yl}carbonyl)amino]-1,3-thiazol-5-yl}sulfanyl)-2,2-dimethylpropanoate;

3-({2-[({3-[(4-methoxyphenyl)sulfanyl]-6-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]pyridin-2-yl}carbonyl)amino]-1,3-thiazol-5-yl}sulfanyl)-2,2-dimethylpropanoic acid;

Methyl 3-{2-[({3-[(4-methoxyphenyl)sulfanyl]-6-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]pyridin-2-yl}carbonyl)amino]-1,3-thiazol-5-yl}propanoate;

3-{2-[({3-[(4-Methoxyphenyl)sulfanyl]-6-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]pyridin-2-yl}carbonyl)amino]-1,3-thiazol-5-yl}propanoic acid;

N-[4-(2-Amino-2-oxoethyl)phenyl]-3-[(4-methoxyphenyl)sulfanyl]-6-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]pyridine-2-carboxamide;

Ethyl ({2-[({3-[(4-methoxyphenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2-yl}carbonyl)amino]-1,3-thiazol-5-yl}sulfanyl)acetate;

({2-[({3-[(4-Methoxyphenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2-yl}carbonyl)amino]-1,3-thiazol-5-yl}sulfanyl)acetic acid;

Ethyl {5-chloro-2-[({3-[(4-methoxyphenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2-yl}carbonyl)amino]-1,3-thiazol-4-yl}acetate;

{5-Chloro-2-[({3-[(4-methoxyphenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2-yl}carbonyl)amino]-1,3-thiazol-4-yl}acetic acid;

Methyl 3-{2-[({3-[(4-methoxyphenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2-yl}carbonyl)amino]-1,3-thiazol-5-yl}propanoate;

3-{2-[({3-[(4-Methoxyphenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2-yl}carbonyl)amino]-1,3-thiazol-5-yl}propanoic acid;

Ethyl {2-[({3-[(4-methoxyphenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2-yl}carbonyl)amino]-1,3-thiazol-4-yl}acetate;

{2-[({3-[(4-Methoxyphenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2-yl}carbonyl)amino]-1,3-thiazol-4-yl}acetic acid;

Ethyl ({5-[({3-[(4-fluorophenyl)sulfanyl]-6-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]pyridin-2-yl}carbonyl)amino]thiophen-2-yl}sulfanyl)acetate;

({2-[({3-[(4-Fluorophenyl)sulfanyl]-6-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]pyridin-2-yl}carbonyl)amino]-1,3-thiazol-5-yl}sulfanyl)acetic acid;

Ethyl 3-({5-[({3-[(4-fluorophenyl)sulfanyl]-6-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]pyridin-2-yl}carbonyl)amino]thiophen-2-yl}sulfanyl)-2,2-dimethylpropanoate;

3-({2-[({3-[(4-Fluorophenyl)sulfanyl]-6-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]pyridin-2-yl}carbonyl)amino]-1,3-thiazol-5-yl}sulfanyl)-2,2-dimethylpropanoic acid;

Ethyl {2-[({3-[(4-fluorophenyl)sulfanyl]-6-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]pyridin-2-yl}carbonyl)amino]-1,3-thiazol-5-yl}acetate;

{2-[({3-[(4-Fluorophenyl)sulfanyl]-6-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]pyridin-2-yl}carbonyl)amino]-1,3-thiazol-5-yl}acetic acid;

Ethyl {5-chloro-2-[({3-[(4-fluorophenyl)sulfanyl]-6-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]pyridin-2-yl}carbonyl)amino]-1,3-thiazol-4-yl}acetate;

{5-Chloro-2-[({3-[(4-fluorophenyl)sulfanyl]-6-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]pyridin-2-yl}carbonyl)amino]-1,3-thiazol-4-yl}acetic acid;

Diethyl ({2-[({3-[(4-fluorophenyl)sulfanyl]-6-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]pyridin-2-yl}carbonyl)amino]-1,3-thiazol-5-yl}methyl)phosphonate;

Ethyl ({5-[({3,6-bis[(4-fluorophenyl)sulfanyl]pyridin-2-yl}carbonyl)amino]thiophen-2-yl}sulfanyl)acetate;

({2-[({3,6-Bis[(4-fluorophenyl)sulfanyl]pyridin-2-yl}carbonyl)amino]-1,3-thiazol-5-yl}sulfanyl)acetic acid;

Ethyl {2-[({3,6-bis[(4-fluorophenyl)sulfanyl]pyridin-2-yl}carbonyl)amino]-5-chloro-1,3-thiazol-4-yl}acetate;

{2-[({3,6-Bis[(4-fluorophenyl)sulfanyl]pyridin-2-yl}carbonyl)amino]-5-chloro-1,3-thiazol-4-yl}acetic acid;

Ethyl {5-chloro-2-[({3-[(4-fluorophenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2-yl}carbonyl)amino]-1,3-thiazol-4-yl}acetate;

{5-Chloro-2-[({3-[(4-fluorophenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2-yl}carbonyl)amino]-1,3-thiazol-4-yl}acetic acid;

Ethyl {2-[({3-[(4-fluorophenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2-yl}carbonyl)amino]-1,3-thiazol-4-yl}acetate;

{2-[({3-[(4-Fluorophenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2-yl}carbonyl)amino]-1,3-thiazol-4-yl}acetic acid;

Ethyl ({2-[({3-[(4-fluorophenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2-yl}carbonyl)amino]-1,3-thiazol-5-yl}sulfanyl)acetate;

({2-[({3-[(4-Fluorophenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2-yl}carbonyl)amino]-1,3-thiazol-5-yl}sulfanyl)acetic acid;

Ethyl 3-({2-[({3-[(4-fluorophenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2-yl}carbonyl)amino]-1,3-thiazol-5-yl}sulfanyl)-2,2-dimethylpropanoate;

3-({2-[({3-[(4-Fluorophenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2-yl}carbonyl)amino]-1,3-thiazol-5-yl}sulfanyl)-2,2-dimethylpropanoic acid;

Methyl 3-{2-[({3-[(4-fluorophenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2-yl}carbonyl)amino]-1,3-thiazol-5-yl}propanoate;

3-{2-[({3-[(4-Fluorophenyl)sulfanyl]-6-(pyridin-2-ylsulfanyl)pyridin-2-yl}carbonyl)amino]-1,3-thiazol-5-yl}propanoic acid;

Ethyl (5-chloro-2-{[(6-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]-3-{[4-(trifluoromethyl)phenyl]sulfanyl}pyridin-2-yl)carbonyl]amino}-1,3-thiazol-4-yl)acetate;

(5-Chloro-2-{[(6-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]-3-{[4-(trifluoromethyl)phenyl]sulfanyl}pyridin-2-yl)carbonyl]amino}-1,3-thiazol-4-yl)acetic acid;

Ethyl [(2-{[(6-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]-3-{[4-(trifluoromethyl)phenyl]sulfanyl}pyridin-2-yl)carbonyl]amino}-1,3-thiazol-5-yl)sulfanyl]acetate;

[(2-{[(6-[(4-Methyl-4H-1,2,4-triazol-3-yl)sulfanyl]-3-{[4-(trifluoromethyl)phenyl]sulfanyl}pyridin-2-yl)carbonyl]amino}-1,3-thiazol-5-yl)sulfanyl]acetic acid;

Diethyl [(2-{[(6-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]-3-{[4-(trifluoromethyl)phenyl]sulfanyl}pyridin-2-yl)carbonyl]amino}-1,3-thiazol-5-yl)methyl]phosphonate;

Ethyl (2-{[(6-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]-3-{[4-(trifluoromethyl)phenyl]sulfanyl}pyridin-2-yl)carbonyl]amino}-1,3-thiazol-4-yl)acetate;

(2-{[(6-[(4-Methyl-4H-1,2,4-triazol-3-yl)sulfanyl]-3-{[4-(trifluoromethyl)phenyl]sulfanyl}pyridin-2-yl)carbonyl]amino}-1,3-thiazol-4-yl)acetic acid;

Methyl 3-(2-{[(6-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]-3-{[4-(trifluoromethyl)phenyl]sulfanyl}pyridin-2-yl)carbonyl]amino}-1,3-thiazol-5-yl)propanoate;

3-(2-{[(6-[(4-Methyl-4H-1,2,4-triazol-3-yl)sulfanyl]-3-{[4-(trifluoromethyl)phenyl]sulfanyl}pyridin-2-yl)carbonyl]amino}-1,3-thiazol-5-yl)propanoic acid;

Diethyl ({2-[({3-[(3,4-dichlorophenyl)sulfanyl]-6-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]pyridin-2-yl}carbonyl)amino]-1,3-thiazol-5-yl}methyl)phosphonate;

Ethyl ({2-[({3-[(3,4-dichlorophenyl)sulfanyl]-6-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]pyridin-2-yl}carbonyl)amino]-1,3-thiazol-5-yl}sulfanyl)acetate;

({2-[({3-[(3,4-Dichlorophenyl)sulfanyl]-6-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]pyridin-2-yl}carbonyl)amino]-1,3-thiazol-5-yl}sulfanyl)acetic acid;

Ethyl {5-chloro-2-[({3-[(3,4-dichlorophenyl)sulfanyl]-6-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]pyridin-2-yl}carbonyl)amino]-1,3-thiazol-4-yl}acetate;

{5-Chloro-2-[({3-[(3,4-dichlorophenyl)sulfanyl]-6-[(4-methyl-4H-1,2,4-triazol-3-yl)sulfanyl]pyridin-2-yl}carbonyl)amino]-1,3-thiazol-4-yl}acetic acid; or

a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition comprising the compound of claim 1 , and a pharmaceutically acceptable carrier.

10. A method for the treatment of a condition selected from obesity or diabetes comprising administering to an individual a pharmaceutical composition comprising the compound or pharmaceutically acceptable salt of claim 1 .

11. The method of claim 10 where the compound or pharmaceutically acceptable salt of claim 1 is used in combination with one or more other active ingredients.

12. A method for the treatment of a condition selected from obesity or diabetes comprising administering to an individual a pharmaceutical composition comprising the compound or pharmaceutically acceptable salt of claim 8 .

13. The method of claim 12 where the compound or pharmaceutically acceptable salt of claim 12 is used in combination with one or more other active ingredients.

Assignments (2)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 12, 2015
From: LIN, SONGNIAN; PARMEE, EMMA R.; XU, JIAYI
To: MERCK SHARP & DOHME CORP.
Reel/Frame 036310/0589 →